FR2881830B1 - PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER - Google Patents

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER

Info

Publication number
FR2881830B1
FR2881830B1 FR0550387A FR0550387A FR2881830B1 FR 2881830 B1 FR2881830 B1 FR 2881830B1 FR 0550387 A FR0550387 A FR 0550387A FR 0550387 A FR0550387 A FR 0550387A FR 2881830 B1 FR2881830 B1 FR 2881830B1
Authority
FR
France
Prior art keywords
treatment
pharmaceutical compositions
prostate cancer
prostate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0550387A
Other languages
French (fr)
Other versions
FR2881830A1 (en
Inventor
Olivier Cussenot
Guy Vallancien
Gaelle Fromont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CT DE RECH POUR LES PATHOLOGIE
Original Assignee
CT DE RECH POUR LES PATHOLOGIE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CT DE RECH POUR LES PATHOLOGIE filed Critical CT DE RECH POUR LES PATHOLOGIE
Priority to FR0550387A priority Critical patent/FR2881830B1/en
Priority to EP06709496A priority patent/EP1851549A2/en
Priority to PCT/FR2006/050117 priority patent/WO2006085033A2/en
Publication of FR2881830A1 publication Critical patent/FR2881830A1/en
Application granted granted Critical
Publication of FR2881830B1 publication Critical patent/FR2881830B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0550387A 2005-02-09 2005-02-09 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER Expired - Fee Related FR2881830B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR0550387A FR2881830B1 (en) 2005-02-09 2005-02-09 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
EP06709496A EP1851549A2 (en) 2005-02-09 2006-02-09 Pharmaceutical compositions for the treatment of prostate cancer
PCT/FR2006/050117 WO2006085033A2 (en) 2005-02-09 2006-02-09 Pharmaceutical compositions for the treatment of prostate cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0550387A FR2881830B1 (en) 2005-02-09 2005-02-09 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER

Publications (2)

Publication Number Publication Date
FR2881830A1 FR2881830A1 (en) 2006-08-11
FR2881830B1 true FR2881830B1 (en) 2007-05-04

Family

ID=34955116

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0550387A Expired - Fee Related FR2881830B1 (en) 2005-02-09 2005-02-09 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER

Country Status (3)

Country Link
EP (1) EP1851549A2 (en)
FR (1) FR2881830B1 (en)
WO (1) WO2006085033A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006831A2 (en) * 1997-07-29 1999-02-11 Dorssers Lambert C J Breast cancer resistance genes, methods for their detection and uses thereof
US20050095592A1 (en) * 2002-02-13 2005-05-05 Jazaeri Amir A. Identification of ovarian cancer tumor markers and therapeutic targets

Also Published As

Publication number Publication date
WO2006085033A3 (en) 2007-01-11
FR2881830A1 (en) 2006-08-11
EP1851549A2 (en) 2007-11-07
WO2006085033A2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
FR21C1062I1 (en) COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
ATE538652T1 (en) SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER
CY2015003I1 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CANCER
MX2009006704A (en) New compounds.
BRPI0719202A2 (en) Diagnosis and treatment of cancer using antiereg antibody
DK1868579T3 (en) Pharmaceutical composition comprising an omega-carboxyaryl sun-substituted diphenylurea for the treatment of cancer
CY2014030I1 (en) THERAPEUTIC COMPOSITIONS INCLUDING INGENOL-3-ANGELATE
DK2474321T3 (en) Compositions for the treatment of collagen-mediated diseases
CL2007000806A1 (en) COMPOUNDS DERIVED FROM REPLACED HETEROPENTACICLOS; PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
ATE434620T1 (en) DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP1928453A4 (en) Methods and compositions for the preventioin and treatment of kidney disease
CL2007000161A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER.
NL1028599A1 (en) Compounds for the treatment of diseases.
CL2007002920A1 (en) COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
CL2007003038A1 (en) COMPOUNDS DERIVED FROM 2-PHENYL-6-AMINOCARBONIL-PYRIMIDINE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
NO20081539L (en) Agent for the treatment of inflammatory bowel disease
ITRM20050179A1 (en) APPLICABLE COMPOSITION FOR THE TREATMENT OF PARADONTAL DISEASES.
DK1803456T5 (en) Pharmaceutical compositions comprising L-733060 for use in the treatment of cancer tumors
FI20095600A (en) Composition for the treatment of skin diseases
DE602006013009D1 (en) PHARMACEUTICAL COMPOSITION OF MAHANINE FOR THE TREATMENT OF PROSTATE CANCER
WO2007086943A3 (en) Wortmannin conjugates and uses thereof
FR2905600B1 (en) TREATMENT OF VERTIGS BY ACETYL-L-LEUCINE.
EP1904088A4 (en) Compositions and methods for the treatment of cancer
ATE544455T1 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT
FR2896678B1 (en) SET CONFIGURE FOR EXFOLIATING THE SKIN

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

ST Notification of lapse

Effective date: 20201006